# US 8,277,831 B2 · Drug-enhanced adhesion prevention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,831 B2
- Document ID: US8277831B2
- Status: Granted
- Kind: B2
- Application number: 10/780,452
- Filed: 2004-02-17
- Published: 2005-08-18
- Granted: 2012-10-02
- Earliest claimed: 2004-02-17
- Assignees: Advanced Technologies and Regenerative Medicine, LLC
- Inventors: Janel E. Young; Scott A. Wadsworth; Kevin Cooper; Joel Rosenblatt; Han Cui
- Web page: https://patentgrep.com/patent/US8277831B2

## CPC

- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering Pemirolast, or an analog thereof, directly to tissue surfaces in the body cavity in amounts and under conditions effective to inhibit formation of adhesions, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure.

## Claims

### Claim 1

A delivery vehicle suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said vehicle comprising Pemirolast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said Pemirolast to said tissue, wherein the delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, fibers, filaments, gels, foams and films, and wherein said delivery vehicle comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(l-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(l-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers, and
the Pemirolast or analog thereof is present in an amount of from about 0.01 milligram Pemirolast or analog thereof per kilogram of the body to about 3,000 milligram Pemirolast or analog thereof per kilogram of the body.

### Claim 2 (depends on 1)

The delivery vehicle of claim 1 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

### Claim 3 (depends on 1)

The delivery vehicle of claim 1 wherein said vehicle comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

### Claim 4 (depends on 1)

The delivery vehicle of claim 1 wherein said vehicle comprises viscous instillate comprising a carrier selected from the group consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

### Claim 5 (depends on 4)

The delivery vehicle of claim 4 wherein said barrier is selected from the group consisting of hyaluronic acids, cellulosics derivatives, collagens, recombinant human collagen, polyethylene glycols, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethyacrylics, aliginates, starches and polypeptides.

### Claim 6 (depends on 1)

The delivery vehicle of claim 1 additionally comprising a second therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

### Claim 7 (depends on 6)

The delivery vehicle of claim 6 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

### Claim 8 (depends on 1)

The delivery vehicle of claim 1 wherein said vehicle provides for single dose administration of said Pemirolast or analog thereof.

### Claim 9

A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition comprising Pemirolast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, and a carrier suitable for local, non-systemic administration of said Pemirolast or analog thereof, wherein the delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, fibers, filaments, gels, foams and films, and wherein said delivery vehicle comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(l-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(l-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers, and
the Pemirolast or analog thereof is present in an amount of from about 0.01 milligram Pemirolast or analog thereof per kilogram of the body to about 3,000 milligram Pemirolast or analog thereof per kilogram of the body.

### Claim 10 (depends on 9)

The composition of claim 9 wherein said composition provides for single dose administration of said Pemirolast or analog thereof.

### Claim 11 (depends on 9)

The composition of claim 9 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

### Claim 12 (depends on 9)

The composition of claim 9 wherein said vehicle comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

### Claim 13 (depends on 9)

The composition of claim 9 wherein said vehicle comprises viscous instillate comprising a carrier selected from the group consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

### Claim 14 (depends on 9)

The composition of claim 9 wherein said barrier is selected from the group consisting of hyaluronic acids, cellulosics derivatives, collagens, recombinant human collagen; polyethylene glycols, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethyacrylics, aliginates, starches and polypeptides.

### Claim 15 (depends on 9)

The composition of claim 9 additionally comprising a second therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

### Claim 16 (depends on 15)

The composition of claim 15 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.
